The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating polypeptides. The methods can involve administering serum amyloid P-component to a patient suffering from CALD or cytokine storm.

Methods are provided for preventing the development of a new allergic condition or the worsening of an existing concomitant allergic condition in a subject having an atopic disease such as atopic dermatitis. In one aspect, the methods comprise administering to the subject a course of therapy of an IL-4/IL-13 antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

It has been established that CD55 expression on human mesenchymal stem cells (hMSCs) is positively correlated with successful allogenic transplantation procedures. Compositions and methods for improved hMSCs, having increased expression of CD55 mRNA and/or increased expression of CD55 on the surface of the cell as compared to a control cell, are provided. Methods include isolating hMSCs from a tissue that naturally has increased CD55 expression, such as adipose tissue derived hMSC (AT-hMSC); and/or in vitro culturing hMSCs in the presence of one or more active agents that stimulates or enhances the expression of CD55 mRNA, and/or increases the surface expression of CD55 in the hMSC to provide improved hMSCs. Preferred active agents include HMG-CoA reductase inhibitors such as atorvastatin and EGFR inhibitors such as erlotinib. Compositions and methods for administering the improved hMSCs to a subject in need thereof are also provided.

It has been established that CD55 expression on human mesenchymal stem cells (hMSCs) is positively correlated with successful allogenic transplantation procedures. Compositions and methods for improved hMSCs, having increased expression of CD55 mRNA and/or increased expression of CD55 on the surface of the cell as compared to a control cell, are provided. Methods include isolating hMSCs from a tissue that naturally has increased CD55 expression, such as adipose tissue derived hMSC (AT-hMSC); and/or in vitro culturing hMSCs in the presence of one or more active agents that stimulates or enhances the expression of CD55 mRNA, and/or increases the surface expression of CD55 in the hMSC to provide improved hMSCs. Preferred active agents include HMG-CoA reductase inhibitors such as atorvastatin and EGFR inhibitors such as erlotinib. Compositions and methods for administering the improved hMSCs to a subject in need thereof are also provided.

Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.

This application relates to compounds of Formula (I):

##STR00001##

or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

This application relates to compounds of Formula (I):

##STR00001##

or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.